Payment overview · 2025
General Payments
$9,485.23
49 reported records · 13 companies
Healthcare provider profile · identity verified
Russ R Ayers, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUGUSTA, GA · NPI 1457556557
Verified facts
What the public records show
CMS Open Payments records show Russ R Ayers, MD received $9,485.23 in general payments during 2025 across 49 reported records.
CSL Plasma Inc. accounted for 94.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CSL Plasma Inc. | Unresolved — no canonical attribution shown | $8,925.00 | 94.1% | 21 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $191.21 | 2.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.63 | 0.8% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $51.97 | 0.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $48.21 | 0.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.95 | 0.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.25 | 0.4% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $23.77 | 0.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.62 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.50 | 0.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.81 | 0.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.57 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.74 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $8,925.00 | 21 |
| Food and Beverage | $560.23 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $136.19 | 6 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $55.02 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.95 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $51.97 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $48.21 | 3 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $46.95 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.33 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 105 |
| Lisinopril | Lisinopril | 234 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 63 |
| Tramadol Hcl | Tramadol Hcl | 182 | 48 |
| Carvedilol | Carvedilol | 179 | 46 |
| Pregabalin | Pregabalin | 167 | 36 |
| Omeprazole | Omeprazole | 166 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 57 |
| Losartan Potassium | Losartan Potassium | 140 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 37 |
| Gabapentin | Gabapentin | 135 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 120 | 26 |
| Furosemide | Furosemide | 119 | 33 |
| Famotidine | Famotidine | 118 | 32 |
| Sertraline Hcl | Sertraline Hcl | 116 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 30 |
| Trazodone Hcl | Trazodone Hcl | 105 | 27 |
| Ozempic | Semaglutide | 100 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 28 |
| Allopurinol | Allopurinol | 94 | 21 |
| Metformin Hcl | Metformin Hcl | 94 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 28 |
| Mounjaro | Tirzepatide | 84 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 19 |
| Naproxen | Naproxen | 74 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 22 |
| Eliquis | Apixaban | 68 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 15 |
| Glipizide | Glipizide | 63 | 19 |
| Spironolactone | Spironolactone | 63 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Donepezil Hcl | Donepezil Hcl | 60 | 18 |
| Potassium Chloride | Potassium Chloride | 60 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Glipizide Er | Glipizide | 53 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 19 |
| Prednisone | Prednisone | 45 | 28 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 20 |
| Meloxicam | Meloxicam | 39 | 17 |
| Topiramate | Topiramate | 39 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Jardiance | Empagliflozin | 34 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Humira(Cf) Pen | Adalimumab | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Celecoxib | Celecoxib | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,485.23 · 49 records | CSL Plasma Inc. | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CABENUVA, DOVATO, Kerendia, Korlym, Ozempic, PIFELTRO, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error